Holen Sie sich die Stockscreener-App
295.02
1.49%
-3.68
Handel nachbörslich:
295.02
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt UTHR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$298.70
Offen:
$295.71
24-Stunden-Volumen:
356.75K
Relative Volume:
0.74
Marktkapitalisierung:
$13.40B
Einnahmen:
$2.76B
Nettoeinkommen (Verlust:
$1.11B
KGV:
12.96
EPS:
22.77
Netto-Cashflow:
$898.10M
1W Leistung:
-2.16%
1M Leistung:
+0.61%
6M Leistung:
-25.97%
1J Leistung:
+12.95%
1-Tages-Spanne:
$290.02
$298.48
1-Wochen-Bereich:
$290.02
$319.40
52-Wochen-Spanne:
$260.41
$417.81
United Therapeutics Corp Stock (UTHR) Company Profile
Firmenname
United Therapeutics Corp
Sektor
Telefon
(301) 608-9292
Adresse
1000 SPRING ST, SILVER SPRING, MD
Vergleichen Sie UTHR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
295.02 | 13.40B | 2.76B | 1.11B | 898.10M | 22.77 |
|
ZTS
Zoetis Inc
|
149.70 | 68.50B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.18 | 48.09B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.67 | 46.12B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.13 | 18.78B | 16.54B | -1.64B | 749.00M | -1.45 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-07-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | Hochstufung | Goldman | Sell → Neutral |
| 2024-02-05 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2022-12-06 | Eingeleitet | UBS | Buy |
| 2022-12-05 | Eingeleitet | Goldman | Sell |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-09-20 | Bestätigt | BofA Securities | Underperform |
| 2022-09-19 | Fortgesetzt | Wedbush | Outperform |
| 2022-02-11 | Eingeleitet | BTIG Research | Neutral |
| 2021-07-14 | Hochstufung | Argus | Hold → Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-02-01 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-06-25 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-03-10 | Hochstufung | Jefferies | Hold → Buy |
| 2020-02-27 | Hochstufung | Cowen | Market Perform → Outperform |
| 2020-01-31 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-12-03 | Eingeleitet | BofA/Merrill | Underperform |
| 2019-08-01 | Hochstufung | Jefferies | Underperform → Hold |
| 2019-08-01 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | Hochstufung | UBS | Sell → Neutral |
| 2019-05-09 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | Hochstufung | Standpoint Research | Hold → Buy |
| 2018-08-08 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | Bestätigt | Barclays | Underweight |
| 2018-01-18 | Fortgesetzt | Credit Suisse | Underperform |
| 2017-12-27 | Bestätigt | Wedbush | Outperform |
| 2017-04-27 | Bestätigt | Wedbush | Outperform |
| 2017-03-30 | Eingeleitet | UBS | Sell |
| 2017-03-16 | Eingeleitet | Credit Suisse | Underperform |
Alle ansehen
United Therapeutics Corp Aktie (UTHR) Neueste Nachrichten
United Therapeutics (UTHR) Target Price Lowered by Argus, Retains Buy Rating | UTHR Stock News - GuruFocus
United Therapeutics (UTHR) Receives Reiterated "Buy" Rating from HC Wainwright | UTHR Stock News - GuruFocus
District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia - GlobeNewswire Inc.
United Therapeutics (UTHR) Gets a Hold from Wells Fargo - The Globe and Mail
BofA raises United Therapeutics stock target to $321 - Investing.com Australia
United Therapeutics (UTHR): Morgan Stanley Raises Price Target | - GuruFocus
BofA raises United Therapeutics stock target to $321 By Investing.com - Investing.com Canada
United Therapeutics (UTHR) Analyst Update: JP Morgan Maintains R - GuruFocus
United Therapeutics (UTHR) Analyst Update: JP Morgan Maintains Rating | UTHR Stock News - GuruFocus
Decoding United Therapeutics Corp (UTHR): A Strategic SWOT Insig - GuruFocus
United Therapeutics Corporation (NASDAQ:UTHR) Q1 2025 Earnings Call Transcript - Insider Monkey
Avepoint, Meta, United Therapeutics - TradingView
United Therapeutics: Q1 Earnings Snapshot - New Haven Register
United Therapeutics Corp (UTHR) Q1 2025 Earnings Call Highlights: Record Revenue and Strategic ... - Yahoo Finance
United Therapeutics Reports Strong Q1 2025 Growth - TipRanks
United Therapeutics Corp. Reports Record Revenue Growth - TipRanks
Earnings call transcript: United Therapeutics Q1 2025 beats expectations - Investing.com
United Therapeutics Corp Surpasses Q1 2025 Estimates with $7.18 EPS and $794.4 Million Revenue - GuruFocus
United Therapeutics (UTHR) Surpasses Q1 Earnings Expectations - GuruFocus
United Therapeutics beats Q1 estimates, shares edge higher - Investing.com
United Therapeutics Q1 Earnings, Revenue Rise - marketscreener.com
United Therapeutics Q1 2025 slides: revenue jumps 17%, organ transplant milestone nears - Investing.com
UNITED THERAPEUTICS Corp SEC 10-Q Report - TradingView
United Therapeutics Sells Priority Review Voucher to AbbVie - CHEManager
United Therapeutics (UTHR) To Report Earnings Tomorrow: Here Is What To Expect - The Globe and Mail
United Therapeutics secures $2.5 billion credit facility - Investing.com
United Therapeutics Enters Credit Agreement With Wells FargoSEC Filing - marketscreener.com
United Therapeutics secures $2.5 billion credit facility By Investing.com - Investing.com UK
United Therapeutics Corporation Announces Credit Agreement Established for A $2.5 Billion Revolving Facility - marketscreener.com
Wells Fargo cuts United Therapeutics stock rating to Equal Weight By Investing.com - Investing.com South Africa
Wells Fargo cuts United Therapeutics stock rating to Equal Weight - Investing.com Australia
This United Therapeutics Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Friday - Benzinga
Demystifying United Therapeutics: Insights From 4 Analyst Reviews - Benzinga
Liquidia Corp files patent infringement suit against United Therapeutics By Investing.com - Investing.com Canada
Liquidia Corp files patent infringement suit against United Therapeutics - Investing.com
BofA Securities Upgrades United Therapeutics to Neutral From Underperform - marketscreener.com
United Therapeutics stock rating lifts to neutral at BofA - Investing.com
United Therapeutics stock rating lifts to neutral at BofA By Investing.com - Investing.com UK
United Therapeutics (UTHR) Stock Upgrade Amid Valuation Drop | U - GuruFocus
United Therapeutics (UTHR) Stock Upgrade Amid Valuation Drop | UTHR Stock News - GuruFocus
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2025 International Conference | UTHR Stock News - GuruFocus
Major Phase 3 Trial Results: United Therapeutics Reveals New Lung Disease Treatment Data at ATS 2025 - Stock Titan
United Therapeutics director Raymond Dwek sells $855,480 in stock - Investing.com Australia
United Therapeutics Schedules Key Q1 2025 Financial Results: What Pharma Investors Should Watch - Stock Titan
United Therapeutics director Raymond Dwek sells $855,480 in stock By Investing.com - Investing.com India
Finanzdaten der United Therapeutics Corp-Aktie (UTHR)
Umsatz
Nettogewinn
Free Cashflow
ENV
United Therapeutics Corp-Aktie (UTHR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| MAHON PAUL A | EVP & GENERAL COUNSEL |
May 01 '25 |
Sale |
300.93 |
11,000 |
3,310,201 |
36,781 |
8.03%
0.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):